Results 201 to 210 of about 218,171 (299)

Structural and temporal dynamics of nano-based therapies in ulcerative colitis: history, hotspots, and emerging trends. [PDF]

Front Immunol
Shi J, Cui D, Yu L, Gong Y.
europepmc   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Laparoscopic management of a huge appendiceal mucocele in a patient with ulcerative colitis: case report and literature review. [PDF]

Int J Surg Case Rep
Aby Hadeer R, Othman M, Nassif M, Farhat H, Tabbikha O, Wakim R.   +5 more
europepmc   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

Pyoderma Gangrenosum of the Eyelid: A Challenging Case. [PDF]

Am J Case Rep
AlAbdullah ZA, Khawjah D, Elewa M, Alsaleh EF.   +3 more
europepmc   +1 more source

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, EarlyView.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Correction: Biomarkers of Probiotic Therapy in Ulcerative Colitis: A Systematic Review of Mechanisms Underlying Remission. [PDF]

Cureus
Farhad ME, Belal I, Baana M, Childs C, Al-Rufayie M.   +4 more
europepmc   +1 more source

Persistence of advanced therapies in patients with ulcerative colitis: real-world data from the nationwide CREdIT registry. [PDF]

Ther Adv Gastroenterol
Hradsky O, Duricova D, Lukas M, Nedbalová L, Pipek B, Drastich P, Falt P, Vanasek T, Svikova J, Siroky M, Bouchner L, Svoboda P, Bronsky J, Bortlik M.   +13 more
europepmc   +1 more source

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange, Tara Sholji, Marra Aghajani, Cindy Kok, John Frew   +4 more
wiley   +1 more source